These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 29950350)

  • 1. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
    Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
    Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.
    Mandikian D; Takahashi N; Lo AA; Li J; Eastham-Anderson J; Slaga D; Ho J; Hristopoulos M; Clark R; Totpal K; Lin K; Joseph SB; Dennis MS; Prabhu S; Junttila TT; Boswell CA
    Mol Cancer Ther; 2018 Apr; 17(4):776-785. PubMed ID: 29339550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
    Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
    Junttila TT; Li J; Johnston J; Hristopoulos M; Clark R; Ellerman D; Wang BE; Li Y; Mathieu M; Li G; Young J; Luis E; Lewis Phillips G; Stefanich E; Spiess C; Polson A; Irving B; Scheer JM; Junttila MR; Dennis MS; Kelley R; Totpal K; Ebens A
    Cancer Res; 2014 Oct; 74(19):5561-71. PubMed ID: 25228655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis.
    Yue C; Shen S; Deng J; Priceman SJ; Li W; Huang A; Yu H
    Cancer Immunol Res; 2015 Aug; 3(8):864-870. PubMed ID: 26025380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation.
    Kamakura D; Asano R; Kawai H; Yasunaga M
    Cancer Immunol Immunother; 2021 Jan; 70(1):177-188. PubMed ID: 32666260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity.
    Herault A; Mak J; de la Cruz-Chuh J; Dillon MA; Ellerman D; Go M; Cosino E; Clark R; Carson E; Yeung S; Pichery M; Gador M; Chiang EY; Wu J; Liang Y; Modrusan Z; Gampa G; Sudhamsu J; Kemball CC; Cheung V; Nguyen TTT; Seshasayee D; Piskol R; Totpal K; Yu SF; Lee G; Kozak KR; Spiess C; Walsh KB
    Cancer Immunol Immunother; 2024 Aug; 73(10):209. PubMed ID: 39112670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
    Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
    Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.
    Benonisson H; Altıntaş I; Sluijter M; Verploegen S; Labrijn AF; Schuurhuis DH; Houtkamp MA; Verbeek JS; Schuurman J; van Hall T
    Mol Cancer Ther; 2019 Feb; 18(2):312-322. PubMed ID: 30381448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease.
    Clancy-Thompson E; Perekslis TJ; Croteau W; Alexander MP; Chabanet TB; Turk MJ; Huang YH; Mullins DW
    Cancer Immunol Res; 2015 Aug; 3(8):956-67. PubMed ID: 26048575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
    Dangaj D; Bruand M; Grimm AJ; Ronet C; Barras D; Duttagupta PA; Lanitis E; Duraiswamy J; Tanyi JL; Benencia F; Conejo-Garcia J; Ramay HR; Montone KT; Powell DJ; Gimotty PA; Facciabene A; Jackson DG; Weber JS; Rodig SJ; Hodi SF; Kandalaft LE; Irving M; Zhang L; Foukas P; Rusakiewicz S; Delorenzi M; Coukos G
    Cancer Cell; 2019 Jun; 35(6):885-900.e10. PubMed ID: 31185212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
    Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
    Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.
    Ovacik AM; Li J; Lemper M; Danilenko D; Stagg N; Mathieu M; Ellerman D; Gupta V; Kalia N; Nguy T; Plaks V; David Johnson C; Wang W; Brumm J; Fine B; Junttila T; Lin K; Carter PJ; Prabhu S; Spiess C; Kamath AV
    MAbs; 2019; 11(2):422-433. PubMed ID: 30550367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
    Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
    Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
    Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
    Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
    Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
    Front Immunol; 2021; 12():654080. PubMed ID: 34040604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
    Wu Z; Guo HF; Xu H; Cheung NV
    Mol Cancer Ther; 2018 Oct; 17(10):2164-2175. PubMed ID: 30082472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3.
    Slaga D; Ellerman D; Lombana TN; Vij R; Li J; Hristopoulos M; Clark R; Johnston J; Shelton A; Mai E; Gadkar K; Lo AA; Koerber JT; Totpal K; Prell R; Lee G; Spiess C; Junttila TT
    Sci Transl Med; 2018 Oct; 10(463):. PubMed ID: 30333240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
    Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.